Table 1 Patient characteristics.
Number | Gender (M/F) | Age | Karyotype (additional abnormality) | Gene mutation | BCR-ABL1 transcript | WBC count at diagnosis (×109/L) | Types of previous TKIs | BCR/ABL copies / 10,000 ABL copies before CAR T-cell therapy | CRS grades | BCR/ABL copies / 10,000 ABL copies at Day 30 after CAR T-cell therapy | Time from CAR T-cell infusion to allo-HSCT (days) | Donor type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 34 | none | none | P210 | 387.6 | Dasatinib | 1277 | 3 | 330 | 51 | MUD |
2 | F | 53 | complex | ETV6 | P210 | 44.6 | Dasatinib | 70 | 0 | 0 | 48 | haplo |
3 | M | 32 | none | none | P190 | 2.5 | Dasatinib | 12 | 1 | 0 | 54 | haplo |
4 | F | 46 | none | none | P190 | 7.7 | Nilotinib | 306 | 1 | 0 | 98 | haplo |
5 | M | 26 | der(20) | none | P190 | 491.1 | Dasatinib | 14 | 0 | 566 | 53 | haplo |
6 | M | 27 | none | none | P190 | 11.4 | Dasatinib | 6 | 0 | 0 | 35 | haplo |
7 | F | 28 | +22, +Ph | BCORL1 | P190 | 67.2 | Imatinib | 49 | 3 | 0 | 35 | haplo |
8 | M | 46 | complex | DNMT3A, FLT3 | P210 | 532.8 | Dasatinib | 96 | 0 | 0 | 57 | haplo |
9 | M | 50 | -7 | EZH2, EGFR | P190 | 100.3 | Dasatinib | 185 | 1 | 184 | 106 | haplo |
10 | F | 57 | none | KMT2C | P190 | 24. 4 | Dasatinib/flumatinib | 30 | 0 | 0 | — | — |
11 | F | 32 | -7 | ASX1 | P210 | 39.4 | Dasatinib | 296 | 0 | 0 | — | — |
12 | F | 29 | none | GATA1, SETD2 | P210 | 128.1 | Imatinib | 2123 | 1 | 0 | — | — |
13 | F | 27 | complex | none | P190 | 20.1 | Imatinib/flumatinib | 18 | 0 | 27 | — | — |
